The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

Hims & Hers Health (HIMS) is down more than -11% after the FDA said Eli Lilly’s weight-loss drugs are no longer considered to be in shortage in the US, which threatens to undercut sales at Hims who ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Stocks declined on Thursday as rising tensions in the Middle East left investors uneasy ahead of September's payrolls report.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Japan's Nikkei Stock 225 closed up by +1.97%. December 10-year T-notes (ZNZ24) Thursday closed down by -16.5 ticks.  The 10-year T-note yield rose +6.3 bp to 3.844%. Dec T-notes Thursday tumbled to a ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...